Novel N -(Heterocyclylphenyl)benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the beta-Catenin Armadillo Repeats Domain as an Anticancer Agent.
Nalli, M., Di Magno, L., Wen, Y., Liu, X., D'Ambrosio, M., Puxeddu, M., Parisi, A., Sebastiani, J., Sorato, A., Coluccia, A., Ripa, S., Di Pastena, F., Capelli, D., Montanari, R., Masci, D., Urbani, A., Naro, C., Sette, C., Orlando, V., D'Angelo, S., Biagioni, S., Bigogno, C., Dondio, G., Pastore, A., Stornaiuolo, M., Canettieri, G., Liu, T., Silvestri, R., La Regina, G.(2023) Acs Pharmacol Transl Sci 6: 1087-1103
- PubMed: 37470018 
- DOI: https://doi.org/10.1021/acsptsci.3c00092
- Primary Citation of Related Structures:  
7ZRB - PubMed Abstract: 
Despite intensive efforts, no inhibitors of the Wnt/β-catenin signaling pathway have been approved so far for the clinical treatment of cancer. We synthesized novel N -(heterocyclylphenyl)benzenesulfonamides as β-catenin inhibitors. Compounds 5 - 10 showed strong inhibition of the luciferase activity. Compounds 5 and 6 inhibited the MDA-MB-231, HCC1806, and HCC1937 TNBC cells. Compound 9 induced in vitro cell death in SW480 and HCT116 cells and in vivo tumorigenicity of a human colorectal cancer line HCT116. In a co-immunoprecipitation study in HCT116 cells transfected with Myc-tagged T-cell factor 4 (Tcf-4), compound 9 abrogated the association between β-catenin and Tcf-4. The crystallographic analysis of the β-catenin Armadillo repeats domain revealed that compound 9 and Tcf-4 share a common binding site within the hotspot binding region close to Lys508. To our knowledge, compound 9 is the first small molecule ligand of this region to be reported. These results highlight the potential of this novel class of β-catenin inhibitors as anticancer agents.
Organizational Affiliation: 
Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, I-00185 Rome, Italy.